id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-N-3083-0003,FDA,FDA-2016-N-3083,"Report on the Performance of Drug and Biologics Firms in Conducting
Postmarketing Requirements and Commitments; Availability",Notice,Notice of Availability,2017-12-08T05:00:00Z,2017,12,2017-12-08T05:00:00Z,,2017-12-08T17:36:17Z,2017-26470,0,0,0900006482cf2abe
FDA-2016-N-3083-0002,FDA,FDA-2016-N-3083,Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability,Notice,Report Submissions,2016-11-28T05:00:00Z,2016,11,2016-11-28T05:00:00Z,,2016-11-28T16:23:03Z,2016-28442,0,0,09000064823c1e69
FDA-2016-N-3083-0001,FDA,FDA-2016-N-3083,Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability,Notice,Renewals,2016-10-31T04:00:00Z,2016,10,2016-10-31T04:00:00Z,,2016-10-31T13:12:42Z,2016-26247,0,0,090000648235e09d